Third Harmonic Bio Inc. (THRD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Third Harmonic Bio Inc. (THRD) has a cash flow conversion efficiency ratio of -0.049x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.48 Million) by net assets ($272.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See THRD equity financing ratio to measure how much of total assets are equity-financed.
Third Harmonic Bio Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Third Harmonic Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore THRD operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Third Harmonic Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Third Harmonic Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lanzhou Zhuangyuan Pasture Co Ltd
SHE:002910
|
0.059x |
|
CSLM Digital Asset Acquisition Corp III, Ltd
NASDAQ:KOYN
|
-0.002x |
|
Keysino Separation Technology Inc
SHE:300899
|
0.007x |
|
CS Disco LLC
NYSE:LAW
|
-0.094x |
|
Bank Net Indonesia Syariah Tbk PT
JK:BANK
|
0.194x |
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
N/A |
|
Highlight Tech
TWO:6208
|
0.085x |
|
GDI Property Group
AU:GDI
|
0.019x |
Annual Cash Flow Conversion Efficiency for Third Harmonic Bio Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Third Harmonic Bio Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see THRD company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $285.15 Million | $-34.50 Million | -0.121x | -59.41% |
| 2023-12-31 | $269.08 Million | $-20.43 Million | -0.076x | +37.16% |
| 2022-12-31 | $289.07 Million | $-34.92 Million | -0.121x | -135.83% |
| 2021-12-31 | $-46.71 Million | $-15.75 Million | 0.337x | -32.64% |
| 2020-12-31 | $-18.36 Million | $-9.19 Million | 0.500x | -- |
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more